Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells.

Rasool N, LaRochelle W, Zhong H, Ara G, Cohen J, Kohn EC.

Clin Cancer Res. 2010 Jan 15;16(2):600-9. doi: 10.1158/1078-0432.CCR-09-1979. Epub 2010 Jan 12.

2.

Homodimerization controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent diffusion in the extracellular matrix.

Kalinina J, Byron SA, Makarenkova HP, Olsen SK, Eliseenkova AV, Larochelle WJ, Dhanabal M, Blais S, Ornitz DM, Day LA, Neubert TA, Pollock PM, Mohammadi M.

Mol Cell Biol. 2009 Sep;29(17):4663-78. doi: 10.1128/MCB.01780-08. Epub 2009 Jun 29.

3.

Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate.

Qian X, Mills E, Torgov M, LaRochelle WJ, Jeffers M.

Mol Oncol. 2008 Jun;2(1):81-93. doi: 10.1016/j.molonc.2008.02.002. Epub 2008 Feb 16.

4.

Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation.

Ara G, Watkins BA, Zhong H, Hawthorne TR, Karkaria CE, Sonis ST, Larochelle WJ.

Int J Radiat Biol. 2008 May;84(5):401-12. doi: 10.1080/09553000802007601.

PMID:
18464069
5.

Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer.

Qian X, Ara G, Mills E, LaRochelle WJ, Lichenstein HS, Jeffers M.

Int J Cancer. 2008 Mar 15;122(6):1400-10.

6.

FGFR2IIIb signaling regulates thymic epithelial differentiation.

Dooley J, Erickson M, Larochelle WJ, Gillard GO, Farr AG.

Dev Dyn. 2007 Dec;236(12):3459-71.

7.

Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB.

Pollack VA, Alvarez E, Tse KF, Torgov MY, Xie S, Shenoy SG, MacDougall JR, Arrol S, Zhong H, Gerwien RW, Hahne WF, Senter PD, Jeffers ME, Lichenstein HS, LaRochelle WJ.

Cancer Chemother Pharmacol. 2007 Aug;60(3):423-35. Epub 2007 Jun 1.

PMID:
17541593
8.

PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis.

Boor P, Konieczny A, Villa L, Kunter U, van Roeyen CR, LaRochelle WJ, Smithson G, Arrol S, Ostendorf T, Floege J.

Nephrol Dial Transplant. 2007 May;22(5):1323-31. Epub 2007 Feb 17.

PMID:
17308324
9.

Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies.

Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M, Lichenstein HS, Jeffers M.

Mol Cancer Ther. 2006 Aug;5(8):2086-95.

10.

Biological responses to PDGF-BB versus PDGF-DD in human mesangial cells.

van Roeyen CR, Ostendorf T, Denecke B, Bokemeyer D, Behrmann I, Strutz F, Lichenstein HS, LaRochelle WJ, Pena CE, Chaudhuri A, Floege J.

Kidney Int. 2006 Apr;69(8):1393-402.

11.

CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.

Tse KF, Jeffers M, Pollack VA, McCabe DA, Shadish ML, Khramtsov NV, Hackett CS, Shenoy SG, Kuang B, Boldog FL, MacDougall JR, Rastelli L, Herrmann J, Gallo M, Gazit-Bornstein G, Senter PD, Meyer DL, Lichenstein HS, LaRochelle WJ.

Clin Cancer Res. 2006 Feb 15;12(4):1373-82.

12.

Angioarrestin: a unique angiopoietin-related protein with anti-angiogenic properties.

Dhanabal M, Jeffers M, LaRochelle WJ, Lichenstein HS.

Biochem Biophys Res Commun. 2005 Jul 29;333(2):308-15. Review.

PMID:
15950186
13.

Recombinant semaphorin 6A-1 ectodomain inhibits in vivo growth factor and tumor cell line-induced angiogenesis.

Dhanabal M, Wu F, Alvarez E, McQueeney KD, Jeffers M, MacDougall J, Boldog FL, Hackett C, Shenoy S, Khramtsov N, Weiner J, Lichenstein HS, LaRochelle WJ.

Cancer Biol Ther. 2005 Jun;4(6):659-68. Epub 2005 Jun 11.

PMID:
15917651
14.

Anti-angiogenic therapy as a cancer treatment paradigm.

Dhanabal M, Jeffers M, Larochelle WJ.

Curr Med Chem Anticancer Agents. 2005 Mar;5(2):115-30. Review.

PMID:
15777219
15.

Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis.

Alvarez E, Fey EG, Valax P, Yim Z, Peterson JD, Mesri M, Jeffers M, Dindinger M, Twomlow N, Ghatpande A, LaRochelle WJ, Sonis ST, Lichenstein HS.

Clin Cancer Res. 2003 Aug 15;9(9):3454-61.

16.

A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis.

Ostendorf T, van Roeyen CR, Peterson JD, Kunter U, Eitner F, Hamad AJ, Chan G, Jia XC, Macaluso J, Gazit-Bornstein G, Keyt BA, Lichenstein HS, LaRochelle WJ, Floege J.

J Am Soc Nephrol. 2003 Sep;14(9):2237-47.

17.

Fibroblast growth factors in cancer: therapeutic possibilities.

Jeffers M, LaRochelle WJ, Lichenstein HS.

Expert Opin Ther Targets. 2002 Aug;6(4):469-82. Review.

PMID:
12223061
18.

Angioarrestin: an antiangiogenic protein with tumor-inhibiting properties.

Dhanabal M, LaRochelle WJ, Jeffers M, Herrmann J, Rastelli L, McDonald WF, Chillakuru RA, Yang M, Boldog FL, Padigaru M, McQueeney KD, Wu F, Minskoff SA, Shimkets RA, Lichenstein HS.

Cancer Res. 2002 Jul 1;62(13):3834-41.

19.

Platelet-derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer.

LaRochelle WJ, Jeffers M, Corvalan JR, Jia XC, Feng X, Vanegas S, Vickroy JD, Yang XD, Chen F, Gazit G, Mayotte J, Macaluso J, Rittman B, Wu F, Dhanabal M, Herrmann J, Lichenstein HS.

Cancer Res. 2002 May 1;62(9):2468-73.

20.

PDGF-D, a new protease-activated growth factor.

LaRochelle WJ, Jeffers M, McDonald WF, Chillakuru RA, Giese NA, Lokker NA, Sullivan C, Boldog FL, Yang M, Vernet C, Burgess CE, Fernandes E, Deegler LL, Rittman B, Shimkets J, Shimkets RA, Rothberg JM, Lichenstein HS.

Nat Cell Biol. 2001 May;3(5):517-21.

PMID:
11331882
21.
22.

Identification of a novel human fibroblast growth factor and characterization of its role in oncogenesis.

Jeffers M, Shimkets R, Prayaga S, Boldog F, Yang M, Burgess C, Fernandes E, Rittman B, Shimkets J, LaRochelle WJ, Lichenstein HS.

Cancer Res. 2001 Apr 1;61(7):3131-8.

23.

Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment.

Seo MS, Okamoto N, Vinores MA, Vinores SA, Hackett SF, Yamada H, Yamada E, Derevjanik NL, LaRochelle W, Zack DJ, Campochiaro PA.

Am J Pathol. 2000 Sep;157(3):995-1005.

24.

Avidin- or streptavidin-biotin as a highly sensitive method to stain total protein on membranes.

Santora KE, Nelson SA, Lewis KA, LaRochelle WJ.

Mol Biotechnol. 2000 Jun;15(2):161-5.

PMID:
10949830
25.

Isolation and characterization of a novel PDGF-induced human gene.

Nelson SA, Santora KE, LaRochelle WJ.

Gene. 2000 Jul 25;253(1):87-93.

PMID:
10925205
26.

Interleukin-15 induces rapid tyrosine phosphorylation of STAT6 and the expression of interleukin-4 in mouse mast cells.

Masuda A, Matsuguchi T, Yamaki K, Hayakawa T, Kubo M, LaRochelle WJ, Yoshikai Y.

J Biol Chem. 2000 Sep 22;275(38):29331-7.

27.
28.

Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis.

Otsuka T, Jakubczak J, Vieira W, Bottaro DP, Breckenridge D, Larochelle WJ, Merlino G.

Mol Cell Biol. 2000 Mar;20(6):2055-65.

29.

Platelet-derived growth factor-A-induced retinal gliosis protects against ischemic retinopathy.

Yamada H, Yamada E, Ando A, Seo MS, Esumi N, Okamoto N, Vinores M, LaRochelle W, Zack DJ, Campochiaro PA.

Am J Pathol. 2000 Feb;156(2):477-87.

30.

Consequences of Stat6 deletion on Sis/PDGF- and IL-4-induced proliferation and transcriptional activation in murine fibroblasts.

Kriebel P, Patel BK, Nelson SA, Grusby MJ, LaRochelle WJ.

Oncogene. 1999 Dec 2;18(51):7294-302.

31.

Heparan sulfate proteoglycan modulates keratinocyte growth factor signaling through interaction with both ligand and receptor.

LaRochelle WJ, Sakaguchi K, Atabey N, Cheon HG, Takagi Y, Kinaia T, Day RM, Miki T, Burgess WH, Bottaro DP.

Biochemistry. 1999 Feb 9;38(6):1765-71.

PMID:
10026256
32.

c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype.

Otsuka T, Takayama H, Sharp R, Celli G, LaRochelle WJ, Bottaro DP, Ellmore N, Vieira W, Owens JW, Anver M, Merlino G.

Cancer Res. 1998 Nov 15;58(22):5157-67.

33.

Localization of the human stat6 gene to chromosome 12q13.3-q14.1, a region implicated in multiple solid tumors.

Patel BK, Keck CL, O'Leary RS, Popescu NC, LaRochelle WJ.

Genomics. 1998 Sep 1;52(2):192-200.

PMID:
9782085
34.
35.

NK1, a natural splice variant of hepatocyte growth factor/scatter factor, is a partial agonist in vivo.

Jakubczak JL, LaRochelle WJ, Merlino G.

Mol Cell Biol. 1998 Mar;18(3):1275-83.

36.
37.
38.

Cloning and characterization of the mouse homolog of the human A6 gene.

Beeler JF, Patel BK, Chedid M, LaRochelle WJ.

Gene. 1997 Jul 1;193(1):31-7.

PMID:
9249064
39.

Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization.

Okamoto N, Tobe T, Hackett SF, Ozaki H, Vinores MA, LaRochelle W, Zack DJ, Campochiaro PA.

Am J Pathol. 1997 Jul;151(1):281-91.

40.

Jak1 expression is required for mediating interleukin-4-induced tyrosine phosphorylation of insulin receptor substrate and Stat6 signaling molecules.

Chen XH, Patel BK, Wang LM, Frankel M, Ellmore N, Flavell RA, LaRochelle WJ, Pierce JH.

J Biol Chem. 1997 Mar 7;272(10):6556-60.

41.

Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas.

Diez de Medina SG, Chopin D, El Marjou A, Delouvée A, LaRochelle WJ, Hoznek A, Abbou C, Aaronson SA, Thiery JP, Radvanyi F.

Oncogene. 1997 Jan 23;14(3):323-30.

42.

Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor.

Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, Aaronson SA, Merlino G.

Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):701-6.

43.

Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease.

Vinores SA, Youssri AI, Luna JD, Chen YS, Bhargave S, Vinores MA, Schoenfeld CL, Peng B, Chan CC, LaRochelle W, Green WR, Campochiaro PA.

Histol Histopathol. 1997 Jan;12(1):99-109.

PMID:
9046048
44.

Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers.

Sakata H, Takayama H, Sharp R, Rubin JS, Merlino G, LaRochelle WJ.

Cell Growth Differ. 1996 Nov;7(11):1513-23.

45.

Stat6 and Jak1 are common elements in platelet-derived growth factor and interleukin-4 signal transduction pathways in NIH 3T3 fibroblasts.

Patel BK, Wang LM, Lee CC, Taylor WG, Pierce JH, LaRochelle WJ.

J Biol Chem. 1996 Sep 6;271(36):22175-82.

47.

Structural role of extracellular domain 1 of alpha-platelet-derived growth factor (PDGF) receptor for PDGF-AA and PDGF-BB binding.

Mahadevan D, Yu JC, Saldanha JW, Thanki N, McPhie P, Uren A, LaRochelle WJ, Heidaran MA.

J Biol Chem. 1995 Nov 17;270(46):27595-600.

48.

Modulation of keratinocyte growth factor and its receptor in reepithelializing human skin.

Marchese C, Chedid M, Dirsch OR, Csaky KG, Santanelli F, Latini C, LaRochelle WJ, Torrisi MR, Aaronson SA.

J Exp Med. 1995 Nov 1;182(5):1369-76.

49.

Isoforms of platelet-derived growth factor and its receptors in epiretinal membranes: immunolocalization to retinal pigmented epithelial cells.

Vinores SA, Henderer JD, Mahlow J, Chiu C, Derevjanik NL, Larochelle W, Csaky C, Campochiaro PA.

Exp Eye Res. 1995 Jun;60(6):607-19.

PMID:
7641844
50.

Hair follicle development and hair growth from defined cell populations grafted onto nude mice.

Lichti U, Scandurro AB, Kartasova T, Rubin JS, LaRochelle W, Yuspa SH.

J Invest Dermatol. 1995 May;104(5 Suppl):43S-44S. No abstract available.

Supplemental Content

Loading ...
Support Center